Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeLatest newsChairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine
      lede-alex-gorsky-financial-time-3.jpg

      Chairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine

      The article explores what guided the decision, which is just the latest example of our Chairman and CEO’s people-first approach to leadership at our healthcare company.

      Share Article
      share to

      Johnson & Johnson scientists are fast at work on a potential vaccine for COVID-19 that our company plans to provide on a not-for-profit basis.

      It’s a decision that underscores our company’s deep commitment to its 77-year-old mission statement, known as Our Credo, which states that Johnson & Johnson’s “first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality.”

      That commitment permeates the decisions that Gorsky makes both inside and outside our company, especially during this coronavirus pandemic.

      In this Financial Times profile, read about the decision to make the vaccine available on a not-for-profit basis, his work to help redefine the purpose of corporations through the U.S. Business Roundtable—and his people-first approach to leading at Johnson & Johnson.

      Read the article: Johnson & Johnson Chief Looks to the Greater Good

      How Johnson & Johnson Is Responding to the COVID-19 Pandemic

      Learn about the innovative ways the company is mobilizing to help combat the global outbreak caused by the novel coronavirus.

      More from Johnson & Johnson

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

      What is a gene mutation?

      Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. For DNA Day learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.